NASDAQ · ATAI
Healthcare · Medical - Pharmaceuticals
$7.35
Up+$0.00 (+0.00%)
Updated Sep 12, 2026, 12:17 AM
SID Score
7.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
ATAI closed at $7.35 after 19 trading sessions, up 1.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $7.31 | $7.37 | $7.30 | $7.35 | 9.59M |
| Sep 9, 2026 | $7.32 | $7.33 | $7.28 | $7.29 | 14.86M |
| Sep 8, 2026 | $7.32 | $7.40 | $7.23 | $7.28 | 119.76M |
| Sep 4, 2026 | $7.34 | $7.41 | $7.31 | $7.39 | 10.31M |
| Sep 3, 2026 | $7.346 | $7.43 | $7.32 | $7.34 | 17.48M |
| Sep 2, 2026 | $7.35 | $7.36 | $7.32 | $7.35 | 10.45M |
| Sep 1, 2026 | $7.35 | $7.385 | $7.34 | $7.34 | 5.95M |
| Aug 31, 2026 | $7.30 | $7.38 | $7.29 | $7.34 | 5.22M |
| Aug 28, 2026 | $7.34 | $7.37 | $7.29 | $7.29 | 2.53M |
| Aug 27, 2026 | $7.38 | $7.40 | $7.35 | $7.35 | 3.04M |
| Aug 26, 2026 | $7.40 | $7.44 | $7.38 | $7.39 | 3.74M |
| Aug 25, 2026 | $7.38 | $7.44 | $7.35 | $7.44 | 9.69M |
| Aug 24, 2026 | $7.40 | $7.40 | $7.29 | $7.38 | 12.31M |
| Aug 21, 2026 | $7.41 | $7.45 | $7.38 | $7.38 | 4.31M |
| Aug 20, 2026 | $7.38 | $7.45 | $7.35 | $7.42 | 9.22M |
| Aug 19, 2026 | $7.28 | $7.37 | $7.27 | $7.36 | 9.14M |
| Aug 18, 2026 | $7.25 | $7.325 | $7.24 | $7.29 | 10.49M |
| Aug 17, 2026 | $7.245 | $7.25 | $7.24 | $7.24 | 7.61M |
| Aug 14, 2026 | $7.24 | $7.28 | $7.23 | $7.26 | 6.1M |
The latest Smart Investors Daily articles mentioning ATAI.
ATAI research
Company profile and research snapshot.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Deutsche Bank | Hold | — |
| Jul 20, 2026 | HC Wainwright & Co. | Neutral | — |
| Jul 17, 2026 | Jones Trading | Hold | — |
| Jul 17, 2026 | Jefferies | Hold | — |
| Jul 16, 2026 | Maxim Group | Hold | — |
No generated briefing is available yet.
ChartMill · Sep 5, 2026
ATAI Beckley (NASDAQ:ATAI) clears Minervini Trend Template & high-growth screen with strong momentum and accelerating sales/EPS growth.
Benzinga · Aug 31, 2026
As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the "Merger Agreement"), with Eli Lilly and Company, an Indiana
Yahoo · Aug 31, 2026
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio.
Benzinga · Aug 18, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ATAI.
